Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Other Non-Current Assets: 2019-2025

Historic Other Non-Current Assets for Beam Therapeutics (BEAM) over the last 7 years, with Sep 2025 value amounting to $6.7 million.

  • Beam Therapeutics' Other Non-Current Assets rose 1.63% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 1.63%. This contributed to the annual value of $8.1 million for FY2024, which is 6.59% down from last year.
  • Per Beam Therapeutics' latest filing, its Other Non-Current Assets stood at $6.7 million for Q3 2025, which was up 0.35% from $6.6 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Other Non-Current Assets registered a high of $15.4 million during Q2 2023, and its lowest value of $6.2 million during Q2 2024.
  • In the last 3 years, Beam Therapeutics' Other Non-Current Assets had a median value of $6.7 million in 2025 and averaged $8.2 million.
  • Per our database at Business Quant, Beam Therapeutics' Other Non-Current Assets grew by 20.99% in 2023 and then crashed by 60.10% in 2024.
  • Beam Therapeutics' Other Non-Current Assets (Quarterly) stood at $12.7 million in 2021, then grew by 0.06% to $12.8 million in 2022, then tumbled by 31.64% to $8.7 million in 2023, then dropped by 6.59% to $8.1 million in 2024, then climbed by 1.63% to $6.7 million in 2025.
  • Its last three reported values are $6.7 million in Q3 2025, $6.6 million for Q2 2025, and $6.6 million during Q1 2025.